Sunshine Lake Pharma has synthesized amide pyrrole compounds reported to be useful for the treatment of liver cancer, cirrhosis and hepatitis B virus (HBV) infection.
Apeloa Pharmaceutical and Hangzhou Apeloa Medicine Research Institute have described new N-(benzoyl)-phenylalanine compounds acting as integrin alpha4beta7 (LPAM-1) antagonists reported to be useful for the treatment of inflammatory bowel disease.
Guangdong Newopp Biopharmaceuticals has disclosed Son of sevenless homolog 1 (SOS1)/GTPase KRAS interaction inhibitors reported to be useful for the treatment of cancer.
Despite new laws and enforcement efforts, protecting intellectual property (IP) rights in China remains a big challenge for companies based in the U.S. and other countries. A case in point is China’s new patent law that came into effect in June 2021.
Jingrui Biopharma has described bromodomain and extra-terminal (BET) inhibitors, particularly bromodomain-containing protein 4 (BD1 domain) (Brd4 BD1) inhibitors, reported to be useful for the treatment of cancer.
Medshine Discovery has disclosed pyrazolopyrazine-linked tricyclic compounds acting as tyrosine-protein phosphatase non-receptor type 11 (PTPN11) inhibitors reported to be useful for the treatment of cancer.
MagicMed Industries has divulged new prenylated psilocybin derivatives acting as 5-HT2A and/or 5-HT1A receptor modulators reported to be useful for the treatment of psychiatric disorders.
Metabrain Research and Shanghai Visonpharma have presented macrocyclic Toll-like receptor 7 (TLR7) agonists reported to be useful for the treatment of hepatitis B virus (HBV), HCV, HIV and influenza virus infections, and cancer.
Allorion Therapeutics has divulged imidazolopyridazines or pyrazolopyrimidines acting as nonreceptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of psoriasis, psoriatic arthritis, ulcerative colitis, Crohn's disease and systemic lupus erythematosus.
The question of whether an artificial intelligence (AI) algorithm should enjoy the status of an inventor has been making the rounds in various nations, but the U.S. Court of Appeals for the Federal Circuit has rejected the notion based on a plain reading of the statute. The court said that the statute is unambiguous in that only natural persons can claim inventorship, but the question will be appealed to the Supreme Court, which will have an opportunity to put this debate to rest.
RSS
